P2, N=92, Not yet recruiting, Philogen S.p.A.

P2, N=92, Not yet recruiting, Philogen S.p.A.

P2, N=180, Not yet recruiting, Philogen S.p.A.

Furthermore, binding in cis-configuration is expected to follow a "bell-shaped" relationship with drug concentration such that high concentrations may lead to reduced benefit/risk ratio compared with concentrations around the peak of the bell-shape. Model simulations identify patient cohorts for whom the upper limit of the pharmacological dosing range may be defined by either undesirable off-tumor target engagement or a decrease in on-tumor cis-binding.

P3, N=456, Terminated, Mural Oncology, Inc | Trial completion date: May 2027 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: May 2026 --> Jan 2025; Study terminated due to business and strategic decision.

P2, N=66, Not yet recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Nemvaleukin demonstrated pharmacodynamic proof of mechanism, with single-agent antitumor activity and manageable safety in patients with advanced melanoma and RCC.

P2, N=27, Terminated, Ascendis Pharma A/S | Trial primary completion date: Dec 2024 --> Mar 2025

ANV600 represents a novel approach to delivering IL-2Rβγ agonism specifically to PD-1+ cells while preserving the binding site for PD-1 checkpoint inhibitors. By targeting a non-blocking epitope on PD-1, ANV600 enables the selective expansion of tumor-reactive CD8+ T cells while allowing independent and optimized dosing of both agents. This design ensures combinability with PD-1 inhibitors at clinically relevant doses, including in patients previously treated with checkpoint blockade. These findings support the clinical development of ANV600 as both a monotherapy and a combination therapy in cancer immunotherapy.

P2, N=27, Terminated, Ascendis Pharma A/S | Completed --> Terminated; The Sponsor made the decision to close enrollment as part of a strategic portfolio review.

In vivo, leukopenia models induced by irradiation and cyclophosphamide were established in zebrafish and mice to determine MC's effect on neutrophil recovery...Notably, the upregulation of RASGRP1 by MC supports the generation of fully functional neutrophils, compared to those induced by G-CSF and GM-CSF alone. This study provides the first evidence that MC promotes neutrophil generation and antimicrobial activity through the IL-23R-mediated pathway, offering a promising therapeutic strategy for leukopenia.

P=N/A, N=70, Not yet recruiting, Centre Hospitalier Universitaire de Nice